推荐产品
形式
powder
质量水平
包含
arginine as stabilizer (~50%)
抗生素抗菌谱
Gram-negative bacteria
Gram-positive bacteria
作用机制
cell wall synthesis | interferes
储存温度
-10 to -25°C
SMILES字符串
O=S([O-])(O)=O.OC(C1=C(C[N+]2=CC(NC(NCCN)=O)=C(N2C)N)CS[C@@]([C@@H]3NC(/C(C4=NSC(N)=N4)=N\OC(C)(C)C(O)=O)=O)([H])N1C3=O)=O
InChI
1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11-;/t12-,18-;/m1./s1
InChI key
UJDQGRLTPBVSFN-TVNHLQOTSA-N
一般描述
Ceftolozane is a novel oxyimino-aminothiazolyl cephalosporin compound. It was formerly known as CXA-101 and FR264205. Ceftolozane is structurally similar to ceftazidime with an amino-thiadiazole ring on the 7-position side chain.
生化/生理作用
Ceftolozane is an antipseudomonal β-lactam inhibitor. It is also a PBP3 inhibitor with a higher affinity for PBP1b compared with other β-lactam inhibitors. Ceftolozane is stable in human plasma, but a low plasma protein binding (20%). It is primarily excreted through urine unchanged. Ceftolozane is a potent antibiotic against Gram-negative bacteria like P. aeruginosa, and Enterobacteriaceae.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.
Mai-Chi Hong et al.
Infection and drug resistance, 6, 215-223 (2013-12-19)
The management of infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, continues to be a significant challenge to clinicians. Ceftolozane/tazobactam is a novel antibacterial and β-lactamase-inhibitor combination that has shown appreciable activity against wild-type Enterobacteriaceae and potent activity against
Jens Martens-Lobenhoffer et al.
Journal of pharmacological and toxicological methods, 103, 106692-106692 (2020-03-17)
Ceftolozane is a newer β-lactam antibiotic drug effective against gram-negative pathogens. Its pharmacokinetic parameters are dominated by the patients' kidney function. Consequently, in patients with impaired kidney function or those who are treated with different forms of renal replacement therapy
Fekade B Sime et al.
Antimicrobial agents and chemotherapy, 63(10) (2019-07-31)
Evaluation of dosing regimens for critically ill patients requires pharmacokinetic data in this population. This prospective observational study aimed to describe the population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal impairment and to assess the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门